“Afrigen Biologics has earned GMP certification for its Cape Town-based mRNA facility, validating compliance with global safety and quality standards. This achievement positions South Africa as a continental hub for vaccine innovation, reducing dependency on imported biologics and enhancing Africa’s pandemic response capacity.”
On 23 August 2026, Afrigen Biologics announced that its Cape Town mRNA manufacturing facility had officially secured Good Manufacturing Practice (GMP) certification from the South African Health Products Regulatory Authority (SAHPRA). This milestone represents a continental breakthrough in biotechnology, as Africa now possesses the infrastructure and regulatory approval to produce investigational biological products for clinical trials.
Why GMP Certification Matters
- Global Standards Compliance: GMP certification ensures adherence to internationally recognized safety and quality benchmarks, a prerequisite for clinical trial readiness.
- Clinical Trial Readiness: Afrigen can now manufacture investigational vaccines for Phase I and II trials, accelerating innovation.
- Health Sovereignty: By reducing reliance on imported vaccines, South Africa strengthens its ability to respond to pandemics locally.
This achievement directly addresses vulnerabilities exposed during the COVID-19 pandemic, when Africa faced severe vaccine shortages due to global inequities in distribution.
Afrigen’s Journey
- 2022–2023: Conceptualization of the mRNA Technology Transfer Programme, co-led by the World Health Organization (WHO) and the Medicines Patent Pool (MPP).
- 2024–2025: Infrastructure development, recruitment of scientists, and establishment of pilot production lines.
- 2026: GMP certification achieved, marking readiness for clinical trial material production.
This timeline reflects a deliberate strategy to build Africa’s biotechnology ecosystem from the ground up.
Strategic Importance
Afrigen’s facility is more than a national achievement—it is a continental asset:
- Pandemic Preparedness: Rapid response capability for emerging infectious diseases.
- Regional Manufacturing Hub: A platform for vaccine production across Africa.
- Innovation Ecosystem: Collaboration between academia, government, and industry to advance biotechnology.
Prof. Petro Terblanche, CEO of Afrigen, emphasized: “This certification is a tribute to the extraordinary commitment of our team. We are ready to support clinical trial production and contribute meaningfully to vaccine development.”
Lessons from COVID-19
The pandemic highlighted Africa’s vulnerability:
- Wealthy nations secured doses early.
- African countries faced delays and shortages.
- Local manufacturing capacity was minimal.
Afrigen’s facility directly addresses this inequity, ensuring that future pandemics do not leave Africa dependent on external suppliers.
Economic and Industrial Impact
- Job Creation: Hundreds of skilled biotech positions in Cape Town.
- Industrial Capabilities: Strengthening regional value chains in biotechnology.
- Economic Growth: Expanding South Africa’s biotech sector and attracting foreign investment.
This facility contributes to South Africa’s ambition to become a continental leader in biotechnology innovation.
Public Health Impact
- Vaccine Equity: Ensures Africa can produce vaccines tailored to local needs.
- Rapid Response: Capacity to develop vaccines against emerging pathogens.
- Clinical Research: Enables Africa-based trials, reducing reliance on external data.
This development is expected to transform Africa’s role in global health, shifting from consumer to producer of advanced biologics.
